Abbreviations: ERK1/2, extracellular signal-regulated kinase 1/2; JNK, c-Jun N-terminal kinase; LAP, latency associated peptide; LTBP, latent TGF-β binding protein; MAPK, mitogen activated protein kinase; MMP, matrix metalloproteinase; PAI-I, plasminogen activator inhibitor; shRNA, small hairpin RNA; TAK1, TGF-β-activated kinase-1; TGF-β, transforming growth factor beta; TβRI, Type I TGF-beta receptor; TβRII, Type II TGF-beta receptor; VEGF, vascular endothelial growth factor. TGF-β is a multifunctional cytokine that regulates cell proliferation, differentiation and extracellular matrix production (Jennings & Pietenpol, 1998; Verrecchia & Mauviel, 2002) . Deregulation of TGF-β expression or signalling has been implicated in the pathogenesis of a variety of diseases, including cancer and fibrosis. In the brain, TGF-βО is expressed at a very low level that increases dramatically aĞer injury (Lindholm et al., 1992) . Under physiological conditions TGF-βО inhibits proliferation of normal astrocytes, but loses its growth-inhibitory potential towards gliomas, due to alterations in the expression of cell cycle inhibitors. There is growing evidence that in the later stages of cancer development TGF-β is actively secreted by tumour cells and does not 
ACTIVATION OF TRANSFORMING GROWTH FACTOR β
TGF-β is produced and secreted in vivo as a latent complex, in which a dimer of mature growth factor is associated with the pro-peptide. The latent state prevents the cytokine from eliciting a response until certain physiological conditions occur or until the target cell is reached. TGF-β is synthesised as 55-kDa polypeptides, which dimerise shortly aĞer production. Then the precursor molecule is cleaved in the Golgi apparatus by furine-like proteases to form small latent TGF-β (Dubois et al., 1995) . This complex contains the mature 25-kDa protein a non-covalently bound to the N-terminal pro-peptide called LAP -latency associated peptide. Such complex may be secreted, but it usually associates with latent TGF-β binding protein (LTBP) forming large latent TGF-β. LTBPs facilitate TGF-β secretion and address it to the extracellular matrix. Cellular recognition of extracellular matrix-associated LTBP and subsequent recognition of latent TGF-β are essential steps in its activation (Hyytiainen et al., 2004) . The latency proteins also contribute to the cytokine stability. Free TGF-β has a half life of about 2 min, whereas the latent form -90 min.
In vivo TGF-β can be activated in an enzymatic process for example by plasmin, which concentrates at critical sites of the cell surface and is able to release mature cytokine, by cleavage of LAP (Grainger et al., 1995) . Thrombospondin-1 has been reported as another protein that activates TGF-β from small or large latent complexes and may cooperate with the plasmin-mediated process (Ribeiro et al., 1999) . Further proteins participating in TGF-β activation in vivo are: integrins, matrix metalloproteinases (MMP-2 and MMP-9) and calpains. Activation of latent TGF-β is a multi-step process and represents a regulatory stage, which translates into a tight control of active TGF-β formation.
INTRACELLULAR TGF-β SIGNALLING PATHWAYS
TGF-β binds tightly to Type II receptor (TβRII) first; this binding allows subsequent incorporation of Type I receptor (TβRI), forming a large ligand-receptor complex involving a ligand dimer and four receptor molecules. The Type I receptor requires activation by Type II to be functional and able to bind the ligand by itself. Simultaneous binding to TGF-β can induce apoptosis or inhibit proliferation of nontransformed cells but loses its growth-inhibitory potential as cells progress to later stages of tumourigenesis. In the later stages of tumour development TGF-β is actively secreted by tumour cells or stromal cells and contributes to cell growth, invasion, metastasis, and decrease in host anti-tumour immune responses.
TGF-β in tumour pathogenesis
the extracellular domains of both types of the receptors by the dimeric ligand induces a close proximity and a proper conformation of the intracellular kinase domains of the receptors, facilitating the phosphorylation and subsequent activation of the Type I receptor (Shi & Massaque, 2003) . Smad proteins are basic intracellular components of TGF-β signalling (Nakao et al., 1997b) . The MH2 (MAD-homology-2) domain is highly conserved among all Smad proteins and is responsible for receptor interaction, formation of homo-and heteromeric Smad complexes, and direct contact with the nuclear pore complex for shuĴling to the nucleus. Phosphorylation of the two C-terminal serine residues in the SXS motif of the MH2 domain activates the receptor Smad (Souchelnytskyi et al., 1997) . AĞer ligand binding, Smad2/3 is phosphorylated by an active form of Type I receptor (Piek et al., 1999; AĴisano & Wrana, 2002; Shi & Massaque, 2003) and associates with the common Smad4 to form a hetero-oligomeric complex which translocates to the nucleus (Fig. 2) . Following translocation, it binds to a specific DNA sequence in the promoters of target genes to regulate their transcription. The transcriptional response to TGF-β depends also on the activity of Smad transcriptional partners. Most of the Smad partners identified to date (e.g., Fast1, Mixer, Jun/Fos, Runx, ATF3, E2F4/5) are highly responsive to different inputs.
The Smad signalling pathway may be negatively regulated by the inhibitory Smad6 and Smad7 (Nakao et al., 1997a) . Inhibitory Smad7 acts to oppose the signal mediated by Smads by forming stable associations with activated Type I receptors, thus preventing phosphorylation of receptor Smads and acting as a negative feedback regulator (Shi & Massaque, 2003) . Moreover, transcriptionally activated by TGF-β signaling, Smad7 promotes the ubiquitination and degradation of the receptors via Smurf1/2 proteins. Smad6 competes with Smad1 for binding to Smad4 (Massague & WoĴon, 2000; Derynck & Zhang, 2003) .
Although the Smad pathway is widely represented in most of the cell types studied, additional pathways may be activated following treatment with TGF-β in specific contexts (Fig. 2 ). For example, activation of Ras, extracellular signal-regulated kinase 1/2 (ERK1/2), and c-Jun N-terminal kinase (JNK) by TGF-β signalling have been reported in primary intestinal epithelial cells and some breast cancer cell lines (for a review see Mulder et al., 2000) , whereas activation of protein kinase A contributes to TGF-β signalling in murine mesangial cells (Wang et al., TGF-β dimer binds to Type II receptors which leads to association with Type I receptors, conformational changes and activation of kinase domains of the receptors. Smad 2/3 proteins are cytoplasmic molecules which, aĞer receptor activation, are phosphorylated by an active form of Type I receptor and associates with Smad 4. Hetero-oligomeric complex of Smad 2/3-Smad4 translocates to the nucleus and binds to specific DNA sequence in the promoters of target genes. The pathway is regulated by the activity of the inhibitory Smad7. TGF-β can activate several mitogen activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPK. The interaction with these MAP kinases could regulate Smad transcriptional activity in a positive or a negative manner.
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B. Kaminska and others 1998). TGF-β activated kinase-1 (TAK1), a member of the MEKK family and activator of JNK and p38 MAPK pathways (Yamaguchi et al., 1995) , was rapidly activated by TGF-β. Selective activation of p38 MAPK, with no apparent activation of JNK aĞer TGF-βО stimulation was reported for C2C12, Mv1Lu, and HaCaT cells (Hanafusa et al., 1999; Karsdal et al., 2003) .
Recent studies suggest that different signalling modules may be responsible for a unique functions of the cytokine in epithelial cells. MEK, an inducer of Erk, appeared to be a major mediator of TGF-β1-dependent PAI-1 expression and cell motility in renal epithelial cells (Kutz et al., 2001) . TGF-β activates the Ras/MKK4/JNK1 signalling cascade, leading to induction of AP-1 activity, which, in turn, up-regulates uPAR (receptor of urokinase-type plasminogen activator) expression in nontransformed intestinal epithelial cells. Type II TGF-β receptor is required for activation of JNK1 and the resulting up-regulation of uPAR expression (Yue et al., 2004) . In mouse mammary epithelial cells, activation of p38 MAPK is required for TGF-β-induced apoptosis, epithelialto-mesenchymal transition, but not growth arrest (Ungefroren et al., 2003; Yoo et al., 2003) . TGF-β1 signalling potentiates staurosporine-induced apoptosis of renal epithelial cells by a Smad-independent, p38 MAP kinase-dependent mechanism (Dai et al., 2003) . In transformed human epidermal keratinocytes, TGF-β activates differently various MAPKs (Johansson et al., 2000) . p38 MAPK mediates TGF-β-induced expression of MMP-2 and MMP-9 in MCF10A human breast epithelial cells .
REGULATION OF TGF-β EXPRESSION IN TUMOUR CELLS
The promoter regions of genes encoding three mammalian transforming growth factors-β (TGF-β1, 2, 3) show liĴle similarity in sequence, indicating differential transcriptional regulation of the genes, whose protein products are functionally very similar. Inspection of the TGF-β1 and TGF-β3 promoters reveals the presence of several putative regulatory elements, including several Sp1 and AP-1 transcription factor binding sites. Promoter fragments of the TGF-β1 and TGF-β3 genes, but not of TGF-β2, were able to compete for binding of Sp1 to DNA oligomers containing consensus Sp1-binding sites (Geiser et al., 1993 ).
An important property of TGF-β1 is an ability to activate its mRNA expression and thereby its own secretion (Van Obberghen-Schilling et al., 1988; Kim et al., 1990; Jennings et al., 1991; Jachimczak et al., 1996) . The crucial role of the AP-1 transcription factor in the autocrine regulation of TGF-β1 expression has been demonstrated in human lymphoma cells and adenocarcinoma A-549 cells (BirchenallRoberts et al., 1990; Kim et al., 1990) . The authors identified three AP-1-binding elements responsible for the auto-induction. Antisense c-jun and antisense c-fos blocked autocrine TGF-β1-induced expression, confirming an involvement of these two components in the mechanism. This property of TGF-β1 may underlie the observed autocrine growth regulatory effect of the cytokine in glioma cells (Jennings et al., 1991) . Contribution of c-Jun N-terminal kinase (JNK) signalling to the control of TGF-β expression has been proposed aĞer observing that JNK-deficient fibroblasts isolated from Jnk1-/-Jnk2-/-mice constitutively express TGF-β1. Complementation studies demonstrated that JNK is a repressor of TGF-β1 gene expression (Ventura et al., 2004) .
Some studies demonstrated that Cyclosporine A (CsA) induces increased expression of TGF-β in vitro as well as in vivo. CsA stimulated TGF-β 1 promoter-dependent transcription of CAT reporter gene in transiently transfected human A-549 cells as well as the synthesis of TGF-β mRNA in human T cells (Prashar et al., 1995) . Hojo et al. (1999) reported that CsA enhances the TGFβ production in A-549 adenocarcinoma cells that correlated with acquisition of a more aggressive phenotype and their enhanced invasiveness. Glucocorticoid dexamethasone causes a significant decrease in the basal and PMA-induced levels of TGF-β1 mRNA in glial cells but not in T cells (Batuman et al., 1995) .
Also post-transcriptional regulation of TGF-β1 expression has been reported in A-549 and PC-3 human prostate adenocarcinoma cells (Kim et al., 1992 ). An increased level of the protein released to the culture medium does not always correlate with increased mRNA level of TGF-β1. It has been suggested that the 5' untranslated region (UTR) of TGF-β1 mRNA containing a stem-loop element may contribute to enhanced mRNA stability.
ROLE OF TGF-β IN TUMOUR PATHOGENESIS

Alterations of TGF-β signalling pathways contribute to tumour risk
There is growing evidence that alterations in TGF-β signalling pathway components modify cancer risk. Approximately 14% of the general population carry TGFBR1*6A, a variant of the TGFBR1 gene that results in decreased TGF-β-mediated growth inhibition. Recent studies show that the overall cancer risk is increased by 70 and 19% among TGFBR1*6A homozygotes and heterozygotes, respectively (Kaklamani et al., 2003) . This suggests that TGFBR1*6A may contribute to the development of a large proportion of common forms of cancer and may become a target for cancer chemoprevention.
TGF-β in tumour pathogenesis
Mutational inactivation of TGFBR2 is the most common genetic event affecting the TGF-β signalling pathway and occurs in approx. 20-30% of all colon cancers (Biswas et al., 2004) . Using a mouse model that is null for TgĠr2 in the colonic epithelium (Cre-lox inactivation of TGFIIR), the authors demonstrated that a loss of TGFBIIR expression in colon epithelial cells promotes the establishment and progression of azoxymethane-induced colon neoplasms, suggesting that TGFBR2 is a tumour suppressor gene in the colon. While decreased TGF-β signalling increases cancer risk, TGF-β secretion and activated TGF-β signalling enhance the aggressiveness of several types of tumours.
Role of TGF-β in tumour migration
The invasion of neoplastic cells into brain tissue is a pathologic hallmark of gliomas and contributes to the failure of current therapeutic modalities (surgery, radiation and chemotherapy). Glioma cells have the ability to invade as single cells through the unique environment of the normal central nervous system (CNS). The brain parenchyma has a unique composition, mainly hyaluronan and is devoid of rigid protein barriers composed of collagen, fibronectin and laminin. Proteases secreted during glioma progression degrade extracellular matrix allowing tumour cells to spread and diffusely infiltrate the brain parenchyma (Rao, 2003) .
Exogenous TGF-β1 directly increases the motility of glioma cells by enhancing expression of collagen and subunit of α 2,5 , β 3 integrin, as well as by up-regulating the activity of metalloproteinases MMP-2, 9 at the cell surface of glioma cells . Interaction between cell surface receptors such as integrins, and extracellular matrix components, for instance collagen, is essential for tumour metastasis and angiogenesis (Verrecchia & Mauviel, 2002) . Additionally, increased enzymatic degradation of extracellular matrix proteins may facilitate tumour spread (PlaĴen et al., 2001; Wick et al., 2001 ).
TGF-β1 as pro-angiogenic factor
Moreover, TGF-β1 may act as an angiogenic factor promoting neovascularization of the tumour. TGF-β1,2 stimulate production of vascular endothelial growth factor (VEGF), which is a major stimulus in the promotion of angiogenesis, as well as plasminogen activator inhibitor (PAI-I) (Benckert et al., 2003; Sugano et al., 2003) . Both are involved in vascular remodelling which occurs during angiogenesis (Kaur et al., 2004) . TGF-β1 stimulates VEGF 164 via mitogen-activated protein kinase kinase 3 (MKK3) and activation of p38α and p38δ MAPK-dependent pathway in murine mesangial cells (Wang et al., 2004) . Some studies demonstrated that hypoxia and TGF-β signalling pathways can synergize in the regulation of VEGF gene expression at the transcriptional level and cooperate in the induction of the promoter activity of VEGF. This cooperation has been mapped on the human VEGF promoter within a region at -1006 to -954 that contains functional DNA-binding sequences for HIF-1 and Smads (Sanchez-Elsner et al., 2001 ).
Role of TGF-β in tumour-mediated immunosuppression
TGF-β plays a crucial role in the escape of glioma from host immunity. The anti-tumour response in patients with glioma may be ineffective because of a lack of a specific tumour antigen and professional antigen presenting cells in the brain. TGF-β1 enhances this effect by inhibition of MHC class II expression on glioma cells, macrophages and microglia (Lee et al., 1997; Dong et al., 2001; Zagzag et al., 2005) . TGF-β1 exerts an immunosuppressive effect on all cells of the immune system (Jachimczak et al., 1993; Beck et al., 2001; Chen et al., 2005) . The main target of its action are T lymphocytes, which could develop into effector (CD8 + CTL) or helper (CD4 + Th1 or Th2) cells. Although several cytokines have been reported to influence differentiation of naive T cells, TGF-β1 is the most effective inhibitor of their maturation. In the presence of this cytokine, CD8 + failed to come CTL and CD4 + did not achieve the Th1 or Th2 phenotype (Gorelik & Flavell, 2001 ). Th2 differentiation seems to be more sensitive to this effect. There is evidence, that TGF-β1 inhibits generation of cytotoxic CD8 + T cell subpopulation, although the mechanism has not been clarified. TGF-β1 suppresses granzyme B and perforin expression that are crucial for the cytolytic action of cytotoxic lymphocytes (Smyth et al., 1991) .
There are contradictory results concerning the anti-proliferative effect of TGF-β1 on CTL (Inge et al., 1992) . Under some experimental conditions the effect induced by TGF-β1 was due to suppression of such immunostimulatory cytokine expression as INFγ and TNFα or down-regulation of IL-2-mediated proliferative signals (Ranges et al., 1987) . TGF-β1 can also abolish T cell activation by a negative effect on antigen presenting cells, such as dendritic cells. TGF-β1 can also suppress macrophages by down-regulation of TNFα, H 2 O 2 and NO production. Moreover, TGF-β1 enhances the production of immunosuppressive IL-10 by macrophages (Maeda et al., 1995) . Additional targets of TGF-β1-mediated immunosuppression are natural killer (NK) and lymphokine activated killer cells (LAK), as well as neutrophils (Kuppner et al., 1988) .
Blocking of TGF-β1 signalling in the immune system cells led to enhanced anti-tumour response. Both thymoma and melanoma-derived cell lines 334 2005 B. Kaminska and others were eradicated by animals expressing a dominant negative TβRII under the control of a T-specific promoter (Gorelik & Flavell, 2001 ). In addition, CTLs transduced with a vector expressing dominant negative TβRII were resistant to the anti-proliferative and anti-cytotoxic effects of exogenous TGF-β1 in EBVpositive Hodgkin disease (Bollard et al., 2002) . Taken together, efforts to bypass TGF-β-mediated immunosuppression represent an aĴractive therapeutic strategy for the treatment of human cancers, both by directly increasing the efficacy of immunosurveillance and the efficacy of tumour immunotherapy.
DEVELOPMENT OF INHIBITORS OF TGF-β SIGNALLING
The TGF-β signalling pathway is emerging as an aĴractive target in cancer and it is predicted that inhibitors of this pathway will find their way into cancer clinical trials, leading to delays in tumour progression and improvement in overall survival. Blockade of TGF-β action inhibited mammary tumour cell viability, migration, and metastases (Muraoka et al., 2002) . Introduction of dominant negative TGF-β Type II receptors (TβRII) into these cells retards primary tumour and metastases formation and prevents epithelial-to-mesenchymal transition (EMT) (OĞ et al., 1998) . Retrovirus-mediated introduction of a dominant negative TGFIIR to bone marrow cells led to generation of leukocytes capable of potent anti-tumour response and suppression of metastasis in melanoma and prostate cancer model (Shah et al., 2002) . The tumorigenicity of mouse thymoma was suppressed by soluble -TGFIIR therapy (Won et al., 1999) . Table 1 summarizes recent therapeutic approaches targeting the TGF-β pathway. One strategy is based on blocking the interactions between the cytokine and its receptor. For example, an application of soluble TGFIIR or human α2-macroglobulin plasma protein that bind TGF-β isoform, limited the access of the cytokine to the receptor (Won et al., 1999) . Two humanized monoclonal antibodies: CAT-192 specific to TGF-β1 and CAT-152 against TGF-β2, are under clinical trial for treatment of fibrosis (Benigni et al., 2003; Mead et al., 2003) . Positive results of these investigations will encourage application of this strategy to anti-cancer therapy.
The antisense oligonuclotide approach is represented by the AP-12009 molecule blocking TGF-β2 expression in tumour cells (Bogdahn et al., 2004) . Data obtained from phase I/II studies indicated a significant increase in survival time of glioblastoma patients that correlated with the reduction of tumour size by more than 80%. Additionally, a TGF-β1-specific antisense oligonuclotide (AP-11014) designed by the same company, Antisense Pharma, is under preclinical development for human non-small cell lung carcinoma, colorectal and prostate cancer. Recently, an effective strategy based on RNA interference was used to reduce TGF-β activity in malignant cells. Blockade of cytokine expression using siRNA against TGF-β inhibited tumour cell migration, invasiveness and restored anti-tumour immune response in a mouse model of glioma (Friese et al., 2004) . We have applied a similar strategy and developed vectors coding for small hairpin RNA which silence TGF-β receptor Type II gene expression by RNA interference in human glioblastoma cells. Transfection of glioblastoma cells with these vectors effectively diminished the expression of TGFβII receptor, abolished TGF-activated Smad signalling and reduced activation of the PAI-1 promoter (Wesolowska et al., unpublished) .
Another approach is aimed at directly blocking the catalytic activity of TGF receptor kinase. A group of competitive inhibitors of the ATP binding (Sawyer et al., 2004; DaCosta Byfield et al., 2004) . Another small-molecule inhibitor SD-208 appears to be a very potent antagonist of TGF-β receptor. The drug significantly prolonged the survival time of glioma-bearing mice. In the presence of the inhibitor, the immunogenicity of glioma cells was enhanced, while their migratory and invasion properties were diminished (Uhl et al., 2004) . Moreover, small-molecule inhibitors (such as SB-431542) have been developed that target downstream TGF-β signalling and block phosphorylation of Smad proteins, resulting in the inhibition of Smad nuclear translocation. TGF-β-mediated up-regulation of critical genes was abolished in human glioma cells by a treatment with SB-431542 (Inman et al., 2001; Hjelmeland et al., 2003) . However, such an approach will not affect Smad-independent pathways.
A large-molecule antagonist of TGF-β signalling seems to be more selective and may have broader action than small-molecule inhibitors. Despite earlier predictions of severe toxicity, neutralizing antibodies to TGF-β are well tolerated and have potent anti-metastatic activity. Si/shRNAs are recognized as a new class of potential therapeutics against a wide range of diseases. Recent data obtained in several laboratories demonstrate the efficacy of systemically administered shRNA as a therapeutic strategy in experimental cancers. However, the success of this approach will largely depend on efficient delivery of shRNAs to tumour cells. Transfection of shRNA with lentiviral or adeno-associated vectors in cultured mammalian cells and in whole animals may be a promising approach in specific, efficient, and stable knockdown of various genes Tiscornia et al., 2003; Grimm et al., 2005) .
